Loading
Retension Pharmaceuticals, Inc. Stock: price and insider trades · United States
2 insiders bought €331k of shares over the last 90 days, the latest by Keller Eric L., filed 13 Oct 2026.
Cluster: 2 buyers in 30 daysRetension Pharmaceuticals, Inc.: what insiders have been doing
Every trade that managers of Retension Pharmaceuticals, Inc. disclose to SEC (Form 4) is tracked on this page. In the past year (18 October 2025 to 18 October 2026), 12 filings came from 6 insiders.
No insider sold shares on the market over the period. Instead, the filings list 2 purchases totalling €331k, made by 2 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 1 senior executive and 1 chief executive. Biggest ticket of the year: €223k, bought by Keller Eric L. and made public on 13 October 2026.
Within a 30-day window, 1 purchase overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The clock since the last published purchase (13 October 2026) now reads 5 days.
With 12 filings in twelve months, the company is quieter than the median of 19 filings across the 5,810 companies we follow on the same exchange. Looking back to 2026, when coverage begins, insiders filed 2 purchases and no sales.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
12
Thresholds
n/a
Buy Volume
€330,903
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleEric L. Keller1 buy
Franklin M. Berger1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
US$11.63
Analyst consensus
Last declaration on 13 October 2026
Declarations12 total
9,662 sharesCommon StockSEC:0001213900-26-109160:1
31,368 sharesCommon StockSEC:0001213900-26-109160:2
4,026 sharesCommon StockSEC:0001213900-26-109159:0
2,640 sharesCommon StockSEC:0001213900-26-109159:1
5,637 sharesCommon StockSEC:0001213900-26-109158:0
20,800 shares@ US$12.00100.0% of flowCommon StockSEC:0001213900-26-109160:0
Canonical exit: 11 Jan 2027 (T+90)
1,611 sharesCommon StockSEC:0001213900-26-109156:0
2,504 sharesCommon StockSEC:0001213900-26-109156:1
12,517 sharesCommon StockSEC:0001213900-26-109155:0
10,000 shares@ US$12.00Common StockSEC:0001213900-26-109155:1
Canonical exit: 11 Jan 2027 (T+90)
4,026 sharesCommon StockSEC:0001213900-26-109154:0
2,640 sharesCommon StockSEC:0001213900-26-109154:1
12 of 12 declarations
About Retension Pharmaceuticals, Inc.
Retension Pharmaceuticals, Inc. is a company focused on developing innovative pharmaceutical treatments. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
